Compare SAH & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAH | DYN |
|---|---|---|
| Founded | 1997 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 1997 | 2020 |
| Metric | SAH | DYN |
|---|---|---|
| Price | $61.54 | $15.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 17 |
| Target Price | ★ $88.91 | $35.73 |
| AVG Volume (30 Days) | 271.3K | ★ 2.9M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.58 | N/A |
| Revenue | ★ $9,951,630,000.00 | N/A |
| Revenue This Year | $3.60 | N/A |
| Revenue Next Year | $4.33 | N/A |
| P/E Ratio | $17.67 | ★ N/A |
| Revenue Growth | ★ 0.86 | N/A |
| 52 Week Low | $54.11 | $14.00 |
| 52 Week High | $113.67 | $27.31 |
| Indicator | SAH | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 41.20 |
| Support Level | $59.30 | $14.43 |
| Resistance Level | $65.77 | $19.46 |
| Average True Range (ATR) | 2.56 | 0.88 |
| MACD | 0.71 | 0.29 |
| Stochastic Oscillator | 30.07 | 45.28 |
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 107 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 18 EchoPark used-vehicle stores in 10 states, 16 collision centers, and 20 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 56% of new-vehicle revenue. BMW is the largest brand at about 23%. 2025 revenue was $15.2 billion, with Texas and California constituting 51% of the total. EchoPark's portion was $2.1 billion.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.